少妇人妻无码专区毛片_蝌蚪视频窝在线播放_欧美性色欧美A在线播放_尤物在线精品视频_欧美精品国产一区二区三区_在线观看成人无码中文AV天堂不卡

美國(guó)MDS Pharma Services
MDS公司是世界前三大最早進(jìn)入中國(guó)的跨國(guó)合同研究組織之一，其中心實(shí)驗(yàn)室分布于歐美和亞洲，為全球提供一體化的體液分析、數(shù)據(jù)整合及試驗(yàn)項(xiàng)目協(xié)調(diào)管理服務(wù)。該公司北京中心實(shí)驗(yàn)室在中國(guó)首家獲得國(guó)際（CAP）認(rèn)證。

MDS Pharma Services—the science you need.

It starts with knowledge. We employ the best minds in the business—nearly 4,000 of them—all applying their extensive industry-based scientific and regulatory expertise to your research. All working together to smooth the pathway to market for your compound.
It continues with a global infrastructure of facilities strategically located around the world, linked to a robust, integrated IT network with superior reliability. MDS Pharma Services applies its advanced scientific and technological expertise throughout the drug discovery and development process – from lead optimization, pre-IND research, early clinical research (bioequivalence, phases I-IIa) and bioanalysis through to global clinical development (phases II-IV), central lab and centralized cardiac services.

It all comes together via an interconnected network of dedicated teams focused on managing your projects through the drug development continuum. More importantly, our capability and expertise to both customize and execute your research and development programs further accelerate your drug's development.

MDS Pharma Services has created a Drug Development Programs service that tailors our program management approach to meet the specific needs of each client, providing full program and scientific consulting, project management and program facilitation. Our Small Molecule Development Program is just one example of the versatility and scope available through Development and Regulatory Services.

From the start, MDS Pharma Services works with you as an integrated team. Our efforts are led by a senior level scientist/manager experienced in drug development who serves as the program leader. All aspects, including contracting, conduct and follow-up, are addressed through Development and Regulatory Services.


?